Note to the reader
This article presents reflections and socio-economic considerations regarding evidence, regulation, and healthcare structures.
It does not provide medical advice and is not intended to diagnose, treat, or replace professional healthcare or medication.
When Evidence Becomes a Privilege – and the Cost Is Paid by Society
In public discourse, evidence is often presented as something neutral, objective, and universally accessible.
In reality, evidence is expensive, exclusive, and largely available only to those with capital.
This is not a marginal issue.
It is a structural problem with significant social and economic consequences.
Evidence Is Not Neutral – It Is Costly
To document a method according to accepted medical or regulatory standards typically requires:
- large financial investments
- years of work
- access to research institutions
- legal and administrative infrastructure
- often, a patentable product to justify the cost
As a result, only a narrow group of actors can realistically participate.
Pharmaceutical companies and large corporations can afford evidence.
Independent systems, non-patentable methods, and individual frameworks generally cannot.
A System That Favors Products Over Practices
Across much of the world, healthcare evidence systems are built around a specific assumption:
That solutions should be product-based, patentable, and commercially scalable.
This leads to a structural bias toward:
- chemical products over behavioral or structural approaches
- patented solutions over open or shared methods
- interventions that generate profit over practices that reduce long-term costs
This is not free competition.
It is capital-filtered validation.
The Social Cost of a Narrow Evidence Model
Globally, societies spend enormous amounts of public money on medication.
For many people, medication is necessary and life-saving.
This is not in question.
At the same time, it is widely acknowledged that:
- medications are often used long-term
- side effects are common
- symptom management frequently replaces root-cause exploration
Yet far fewer resources are allocated to systematically investigating:
- low-cost, non-patentable approaches
- low-risk methods focused on self-regulation and structure
- practices that could potentially reduce long-term dependency
This imbalance has economic consequences.
When “Lack of Evidence” Becomes a Gatekeeping Tool
Many non-medical methods are dismissed with a familiar phrase:
“There is no evidence.”
Often, this does not mean the method has been disproven.
It means:
“The system is not designed to investigate this type of approach.”
In this way, the demand for evidence can function as a gatekeeping mechanism, protecting existing structures while discouraging exploration outside established commercial models.
A Structural Catch-22
Non-patentable methods face a paradox:
- evidence is required to be taken seriously
- evidence is too expensive to obtain
- costs cannot be recovered because the method cannot be owned
This creates a closed loop in which:
- only commercially protected solutions are studied
- alternatives remain undocumented
- public debate remains artificially narrow
Evidence as a Public Good
Evidence does not have to be a private commodity.
One could imagine systems where:
- public funds support the investigation of non-commercial methods
- research is guided by societal cost-benefit rather than market potential
- low-risk, low-cost approaches are evaluated on their own terms
Not to replace medicine –
but to broaden the knowledge base available to society.
A Political Question, Not a Scientific One
The core issue is not whether evidence matters.
It does.
The real question is:
Who has access to creating evidence – and who is excluded by design?
As long as evidence production is largely tied to capital, patents, and market return, innovation will remain structurally limited.
This is not a failure of science.
It is a policy choice.
Conclusion
When evidence becomes a privilege rather than a shared infrastructure, society pays the price:
- through higher long-term costs
- through reduced innovation
- through an unnecessarily narrow understanding of health
Reconsidering how evidence is funded, prioritized, and evaluated is not radical.
It is economically and socially responsible.
The question is not whether we can afford to explore alternatives.
It is whether we can afford not to.
